<?xml version="1.0" encoding="UTF-8"?>
<p>Maribavir is a promising anti-HCMV compound which is administered orally; however, it is still under advanced clinical trials. The drug targets the viral kinase UL97 which is crucial for the formation of viral teguments and assembly complexes for virion releasing [
 <xref rid="B36-viruses-12-00021" ref-type="bibr">36</xref>]. However, it is not recommended to co-administer maribavir and ganciclovir both in that maribavir is an inhibitor of the UL97 enzyme which is required for the assimilation of ganciclovir. Maribavir potentially substitutes for other traditional anti-HCMV drugs because of its reduced haematotoxicity and nephrotoxicity compared with ganciclovir and valganciclovir [
 <xref rid="B36-viruses-12-00021" ref-type="bibr">36</xref>].
</p>
